US Supreme Court justices divided over Teva MS patent battle

October 15, 2014 18:20

WASHINGTON - The US Supreme Court on Wednesday appeared closely divided as it weighed Teva Pharmaceutical Industries Ltd's high-profile fight with generic drug manufacturers over patent protections for Copaxone, its top-selling multiple sclerosis drug.

Israel-based Teva is battling to protect a key patent for the drug that is due to expire in September 2015. It is one of the most important business cases of the current term for the nine Supreme Court justices.

There are two teams developing cheaper generic forms of Copaxone: one involving Novartis AG's Sandoz Inc and Momenta Pharmaceuticals Inc and another involving Mylan Inc and Natco Pharma Ltd.

Related Content

Breaking news
March 19, 2018
Putin to France's Macron: Claims Russia behind UK spy poisoning unproven


Israel Weather
  • 15 - 34
    Beer Sheva
    16 - 30
    Tel Aviv - Yafo
  • 14 - 27
    15 - 29
  • 18 - 32
    16 - 32